Filtered By:
Source: Clinical Lung Cancer
Drug: Docetaxel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 49 results found since Jan 2013.
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial using real-world data
This study replicated the atezolizumab and docetaxel arms of the OAK trial using RWD and compared progression-free survival (PFS) outcomes derived from abstracted physician's notes in RWD (rwPFS) against PFS outcomes derived from the clinical trial (ctPFS). Atezolizumab and docetaxel arms of the phase III OAK RCT (NCT02008227) were replicated in a US nationwide real-world database using selected OAK inclusion/exclusion criteria and propensity score-based adjustment for baseline prognostic variables. Concordance of outcomes was assessed using Kaplan-Meier (KM) medians and hazard ratios (HRs). The RWD cohorts comprised 133 a...
Source: Clinical Lung Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Shivani K Mhatre Robson J M Machado Thanh G N Ton Huong Trinh Julien Mazieres Achim Rittmeyer Michael T Bretscher Source Type: research
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study
CONCLUSIONS: We found that second-line ICI treatment seemed to have a little impact on OS.PMID:37304652 | PMC:PMC10250914 | DOI:10.1016/j.jtocrr.2023.100514
Source: Clinical Lung Cancer - June 12, 2023 Category: Cancer & Oncology Authors: Yoshihito Kogure Akiko Kada Hiroya Hashimoto Shinji Atagi Yuichi Takiguchi Hideo Saka Noriyuki Ebi Akira Inoue Takayasu Kurata Yuka Fujita Yoichi Nishii Hidetoshi Itani Takeo Endo Akiko M Saito Takuo Shibayama Nobuyuki Yamamoto Akihiko Gemma Source Type: research
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
CONCLUSIONS: RRs were significantly improved in the overall population. Contrary to pre-clinical studies, the combination showed no improvement in efficacy in G12C patients. Co-mutations may influence therapeutic efficacy of KRAS directed therapies and are worthy of further evaluation.PMID:37233987 | DOI:10.1158/1078-0432.CCR-22-3947
Source: Clinical Lung Cancer - May 26, 2023 Category: Cancer & Oncology Authors: Shirish M Gadgeel Jieling Miao Jonathan W Riess James Moon Philip C Mack Gregory J Gerstner Timothy F Burns Asma Taj Wallace L Akerley Konstantin H Dragnev Noel Laudi Mary W Redman Jhanelle E Gray David R Gandara Karen Kelly Source Type: research
The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
CONCLUSIONS: The GENIE BPC cohort provides comprehensive clinico-genomic data for patients with NSCLC, which can improve understanding of real-world patient outcomes.PMID:37223888 | DOI:10.1158/1078-0432.CCR-23-0580
Source: Clinical Lung Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Noura J Choudhury Jessica A Lavery Samantha Brown Ino de Bruijn Justin Jee Thinh Ngoc Tran Hira Rizvi Kathryn C Arbour Karissa Whiting Ronglai Shen Matthew Hellmann Philippe L Bedard Celeste Yu Natasha Leighl Michele LeNoue-Newton Christine Micheel Jeremy Source Type: research
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
CONCLUSION: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m2, the benefits of docetaxel therapy outweigh the risks.PMID:37196430 | DOI:10.1200/JCO.22.02545
Source: Clinical Lung Cancer - May 17, 2023 Category: Cancer & Oncology Authors: Frances A Shepherd Janet Dancey Rodryg Ramlau Karin Mattson Richard Gralla Mark O'Rourke Nathan Levitan Laurent Gressot Mark Vincent Ronald Burkes Susan Coughlin Yong Kim Jocelyne Berille Source Type: research
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
CONCLUSION: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available.PMID:37196429 | DOI:10.1200/JCO.22.02546
Source: Clinical Lung Cancer - May 17, 2023 Category: Cancer & Oncology Authors: Nasser Hanna Frances A Shepherd Frank V Fossella Jose R Pereira Filippo De Marinis Joachim von Pawel Ulrich Gatzemeier Thomas Chang Yao Tsao Miklos Pless Thomas Muller Hong-Liang Lim Christopher Desch Klara Szondy Radj Gervais None Shaharyar Christian Man Source Type: research
Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung Cancer and Pemetrexed Versus Docetaxel in Second-Line Non-Small-Cell Lung Cancer
J Clin Oncol. 2023 May 20;41(15):2671-2672. doi: 10.1200/JCO.22.02871.NO ABSTRACTPMID:37196428 | DOI:10.1200/JCO.22.02871
Source: Clinical Lung Cancer - May 17, 2023 Category: Cancer & Oncology Authors: Thomas E Stinchcombe Source Type: research
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer
CONCLUSION: In this large, multicenter retrospective chart review of patients with KRAS G12C mutant NSCLC we observed a relatively short median rwPFS of 4.6 months among 10 patients with KRAS G12C mutant NSCLC treated with docetaxel with or without ramucirumab in the second-line setting, which aligns with the recently reported CodeBreak 200 dataset.PMID:36841727 | DOI:10.1016/j.cllc.2023.01.009
Source: Clinical Lung Cancer - February 25, 2023 Category: Cancer & Oncology Authors: Wade T Iams Meridith L Balbach Sharon Phillips Adrian Sacher Christine Bestvina Vamsidhar Velcheti Xiao Wang Melina E Marmarelis Nan Sethakorn Ticiana Leal Paul E Sackstein Chul Kim Md Andrew Robinson Kathan Mehta Robert Hsu Jorge Nieva Tejas Patil D Ross Source Type: research
Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study
CONCLUSION: RAM and DOC may be preferably administered after ICI, rather than after CTx alone, BEV, or TKI, and, furthermore, enhanced if the prior ICI has a favorable tumor response.PMID:36773042 | DOI:10.1007/s00228-023-03452-0
Source: Clinical Lung Cancer - February 11, 2023 Category: Cancer & Oncology Authors: Satoshi Tanizaki Kinnosuke Matsumoto Akihiro Tamiya Yoshihiko Taniguchi Yoshinobu Matsuda Junji Uchida Kiyonobu Ueno Hayato Kawachi Motohiro Tamiya Takafumi Yanase Hidekazu Suzuki Kyoichi Okishio Source Type: research
Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment
CONCLUSION: Nab-paclitaxel was found to be tolerable and beneficial for previously treated patients with advanced NSCLC and mild or moderate renal impairment.PMID:36114096 | DOI:10.1016/j.cllc.2022.08.011
Source: Clinical Lung Cancer - September 16, 2022 Category: Cancer & Oncology Authors: Yasuto Yoneshima Satoshi Morita Masahiko Ando Atsushi Nakamura Shunichiro Iwasawa Hiroshige Yoshioka Yasuhiro Goto Masafumi Takeshita Toshiyuki Harada Katsuya Hirano Tetsuya Oguri Masashi Kondo Satoru Miura Yukio Hosomi Terufumi Kato Toshio Kubo Junji Kis Source Type: research
A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-na ïve non-small-cell lung cancer: TORG1630
CONCLUSIONS: Despite the slightly elevated toxicity, the addition of docetaxel to nivolumab has significantly prolonged the OS and PFS of patients with previously treated ICI-naïve NSCLC.PMID:35980349 | DOI:10.1158/1078-0432.CCR-22-1687
Source: Clinical Lung Cancer - August 18, 2022 Category: Cancer & Oncology Authors: Yuri Taniguchi Tsuneo Shimokawa Yuichi Takiguchi Toshihiro Misumi Yukiko Nakamura Yosuke Kawashima Naoki Furuya Yoshimasa Shiraishi Toshiyuki Harada Hisashi Tanaka Satoru Miura Ayumi Uchiyama Yoshiro Nakahara Takaaki Tokito Katsuhiko Naoki Akihiro Bessho Source Type: research
